{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:16:41Z","timestamp":1792819001954,"version":"4.5.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Biologics targeting inflammation-related molecules in the immune system have been developed to treat rheumatoid arthritis (RA), and these RA treatments have provided revolutionary advances. Biologics may also be an effective treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, particularly in patients with resistance to standard treatments. Despite the accumulation of clinical experience and the increasing understanding of the pathogenesis of vasculitis, it is becoming more difficult to cure vasculitis. The treatment of vasculitis with biologics has been examined in clinical trials, and this has also enhanced our understanding of the pathogenesis of vasculitis. A humanized anti-interleukin-5 monoclonal antibody known as mepolizumab was recently demonstrated to provide clinical benefit in the management of eosinophilic granulomatosis with polyangiitis in refractory and relapsing disease, and additional new drugs for vasculitis are being tested in clinical trials, while others are in abeyance. This review presents the new findings regarding biologics in addition to the conventional immunosuppressive therapy for ANCA-associated vasculitis.<\/jats:p>","DOI":"10.3389\/fimmu.2021.631055","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T07:13:51Z","timestamp":1617261231000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuji","family":"Nozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis-clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu237","article-title":"Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: Evaluation of the international histological classification and other prognostic factors","volume":"30","author":"Tanna","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.40471","article-title":"Brief Report: Circulating cytokine profiles and antineutrophil cytoplasmic antibody specificity in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"70","author":"Berti","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener\u2019s granulomatosis: Risks and relation to cyclophosphamide","volume":"63","author":"Knight","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: Core curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00549","article-title":"Eosinophilic granulomatosis with polyangiitis: An overview","volume":"5","author":"Gioffredi","year":"2014","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1993.1020","article-title":"Cellular immune responses and pathogenesis in c-ANCA positive vasculitides","volume":"6","author":"Rasmussen","year":"1993","journal-title":"J Autoimmun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.15171\/jnp.2017.16","article-title":"Differences in the frequency of macrophage and T cell markers between focal and crescentic classes of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis","volume":"6","author":"Kidder","year":"2016","journal-title":"J\u00a0Nephropathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00615.x","article-title":"T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission","volume":"112","author":"King","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH656>3.0.CO;2-M","article-title":"Localized Wegener\u2019s granulomatosis: Predominance of CD26 and IFN-gamma expression","volume":"192","author":"M\u00fcller","year":"2000","journal-title":"J Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.125002332.x","article-title":"Th2 dominance in nasal mucosa in patients with Wegener\u2019s granulomatosis","volume":"125","author":"Balding","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199904)42:4<742::AID-ANR18>3.0.CO;2-I","article-title":"Cytokine profiles in Wegener\u2019s granulomatosis: Predominance of type 1 (Th1) in the granulomatous inflammation","volume":"42","author":"Csernok","year":"1999","journal-title":"Arthritis Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61118-2","article-title":"Peripheral blood and granuloma CD4(+)CD28(\u2013) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener\u2019s granulomatosis","volume":"160","author":"Komocsi","year":"2002","journal-title":"Am J Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-015-0344-z","article-title":"The role of IL-17 and Th17 lymphocytes in autoimmune diseases","volume":"63","author":"Tabarkiewicz","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008080891","article-title":"IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen","volume":"20","author":"Ooi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802246","article-title":"IL-17 induces monocyte migration in rheumatoid arthritis","volume":"182","author":"Shahrara","year":"2009","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.23557","article-title":"Skewed distribution of Th17 lymphocytes in patients with Wegener\u2019s granulomatosis in remission","volume":"58","author":"Abdulahad","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp783","article-title":"Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis","volume":"25","author":"Nogueira","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646810","article-title":"Skewing toward Treg and Th2 responses is a characteristic feature of sustained remission in ANCA-positive granulomatosis with polyangiitis","volume":"47","author":"Szczeklik","year":"2017","journal-title":"Eur J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e18734","DOI":"10.1371\/journal.pone.0018734","article-title":"Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"6","author":"Rimbert","year":"2011","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017090949","article-title":"IL-17C\/IL-17 receptor E signaling in CD4+\u00a0T cells promotes TH17 cell-driven glomerular inflammation","volume":"29","author":"Krohn","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00683.2011","article-title":"Renal IL-17 expression in human ANCA-associated glomerulonephritis","volume":"302","author":"Velden","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-216085","article-title":"Evidence for a cross-talk between human neutrophils and Th17 cells","volume":"115","author":"Pelletier","year":"2010","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1308104","article-title":"Targeted therapy with eculizumab for inherited CD59 deficiency","volume":"370","author":"H\u00f6chsmann","year":"2014","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J Immunol"},{"key":"B38","article-title":"Complement-induced granulocyte aggregation in vivo","volume":"102","author":"Hammerschmidt","year":"1981","journal-title":"Am J Pathol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00063.x","article-title":"ANCA-induced neutrophil F-actin polymerization: Implications for microvascular inflammation","volume":"67","author":"Tse","year":"2005","journal-title":"Kidney Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","article-title":"Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer","volume":"39","author":"Koyama","year":"1977","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.rdc.2009.12.010","article-title":"Gonadal failure with cyclophosphamide therapy for lupus nephritis: Advances in fertility preservation","volume":"36","author":"Mersereau","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"B43","article-title":"Gonadal function in male adolescents and young males with juvenile onset systemic lupus erythematosus","volume":"29","author":"Silva","year":"2002","journal-title":"J Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000055103","article-title":"Impact of chemotherapy on male fertility","volume":"24","author":"Schrader","year":"2001","journal-title":"Onkologie"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20605","article-title":"Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener\u2019s)","volume":"63","author":"Clowse","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/art.22679","article-title":"Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2006.060301","article-title":"Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide","volume":"66","author":"Stassen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr127","article-title":"Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis","volume":"26","author":"Mansfield","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780351113","article-title":"The treatment of Wegener\u2019s granulomatosis with glucocorticoids and methotrexate","volume":"35","author":"Hoffman","year":"1992","journal-title":"Arthritis Rheum"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380505","article-title":"An analysis of forty-two Wegener\u2019s granulomatosis patients treated with methotrexate and prednisone","volume":"38","author":"Sneller","year":"1995","journal-title":"Arthritis Rheum"},{"key":"B55","article-title":"Treatment of non-life threatening Wegener\u2019s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice","volume":"26","author":"Stone","year":"1999","journal-title":"J Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-R","article-title":"Use of methotrexate and glucocorticoids in the treatment of Wegener\u2019s granulomatosis. Long-term renal outcome in patients with glomerulonephritis","volume":"43","author":"Langford","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","author":"Stone","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"B58","article-title":"Induction of remission in Wegener\u2019s granulomatosis with low dose methotrexate","volume":"25","author":"de Groot","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"B59","first-page":"52","article-title":"Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment","volume":"22","author":"Metzler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.34547","article-title":"Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1159\/000324364","article-title":"Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis","volume":"33","author":"Han","year":"2011","journal-title":"Am J Nephrol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/ki.2010.472","article-title":"New pathophysiological insights and treatment of ANCA-associated vasculitis","volume":"79","author":"Wilde","year":"2011","journal-title":"Kidney Int"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/35100573","article-title":"From T to B and back again: Positive feedback in systemic autoimmune disease","volume":"1","author":"Shlomchik","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.6.1504.bloodjournal7361504","article-title":"Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6, and GMCSF","volume":"73","author":"Clutterbuck","year":"1989","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.10.2542.bloodjournal78102542","article-title":"Analysis of the survival of mature human eosinophils: Interleukin-5 prevents apoptosis in mature human eosinophils","volume":"78","author":"Yamaguchi","year":"1991","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J\u00a0Exp Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/science.1061964","article-title":"An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway","volume":"293","author":"Schiemann","year":"2001","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: A tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e5456","DOI":"10.1371\/journal.pone.0005456","article-title":"Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells","volume":"4","author":"Rauch","year":"2009","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1159\/000323393","article-title":"Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: Association with disease activity","volume":"118","author":"Nagai","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1526-z","article-title":"B-lymphocyte activating factor levels are increased in patients with Wegener\u2019s granulomatosis and inversely correlated with ANCA titer","volume":"29","author":"Bader","year":"2010","journal-title":"Clin Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005121359","article-title":"Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases","volume":"17","author":"Feldmann","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb03336.x","article-title":"Enhanced expression of the tumour necrosis factor\/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis","volume":"81","author":"Deguchi","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.98","article-title":"In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis","volume":"43","author":"Noronha","year":"1993","journal-title":"Kidney Int"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"27","year":"2005","journal-title":"N Engl J Med"},{"key":"B80","article-title":"Infliximab or rituximab for refractory Wegener\u2019s granulomatosis: Long-term followup. A prospective randomised multicentre study on 17 patients","volume":"29","author":"de Menthon","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq187","article-title":"Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement","volume":"25","author":"Laurino","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/art.30394","article-title":"Granulomatosis with polyangiitis (Wegener) and solid malignancies among etanercept-treated patients: Long-term follow-up of a multicenter longitudinal cohort","volume":"63","author":"Silva","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01160-2","article-title":"Triple check for antigen specificity of B cells during germinal centre reactions","volume":"18","author":"Lindhout","year":"1997","journal-title":"Immunol Today"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(98)80161-1","article-title":"Germinal centers: Form and function","volume":"10","author":"Tarlinton","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1998.tb01223.x","article-title":"Epitope spreading: The role of self peptides and autoantigen processing by B lymphocytes","volume":"164","author":"Mamula","year":"1998","journal-title":"Immunol Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01575.x","article-title":"Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener\u2019s granulomatosis","volume":"126","author":"Steiner","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-Ig) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90759-A","article-title":"Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy","volume":"341","author":"Lockwood","year":"1993","journal-title":"Lancet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2009\u2013\u2009Results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181347","article-title":"Microparticles expressing myeloperoxidase and complement C3a and C5a as markers of renal involvement in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"47","author":"Antovic","year":"2020","journal-title":"J Rheumatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648","article-title":"The\u00a0complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-017-3077-7","article-title":"Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence","volume":"177","author":"Keenswijk","year":"2018","journal-title":"Eur J Pediatr"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e0164646","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PloS One"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of c5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e16664","DOI":"10.2196\/16664","article-title":"Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide\/azathioprine: Protocol for a randomized, double-blind, active-controlled, Phase 3 trial","volume":"9","author":"Merkel","year":"2020","journal-title":"JMIR Res Protoc"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.631055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T07:14:02Z","timestamp":1617261242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.631055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2021.631055"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.631055","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"article-number":"631055"}}